Desmond Thompson

14.0k total citations · 5 hit papers
86 papers, 10.7k citations indexed

About

Desmond Thompson is a scholar working on Orthopedics and Sports Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Desmond Thompson has authored 86 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Orthopedics and Sports Medicine, 37 papers in Oncology and 24 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Desmond Thompson's work include Bone health and osteoporosis research (38 papers), Bone health and treatments (33 papers) and Retinal Diseases and Treatments (15 papers). Desmond Thompson is often cited by papers focused on Bone health and osteoporosis research (38 papers), Bone health and treatments (33 papers) and Retinal Diseases and Treatments (15 papers). Desmond Thompson collaborates with scholars based in United States, United Kingdom and Japan. Desmond Thompson's co-authors include Dennis M. Black, Kristine E. Ensrud, Jane A. Cauley, Michael C. Nevitt, Douglas C. Bauer, Marc C. Hochberg, Steven R. Cummings, Sara A. Quandt, Harry K. Genant and Susan M. Ott and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Desmond Thompson

83 papers receiving 10.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

1996 2.9k citations Dennis M. Black, Steven R. Cummings et al. The Lancet profile →
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial

2000 785 citations Dennis M. Black, Desmond Thompson et al. The Journal of Clinical Endocrinology & Metabolism profile →
Risk of Mortality Following Clinical Fractures

2000 735 citations Jane A. Cauley, Desmond Thompson et al. Osteoporosis International profile →
Cancer Incidence in Atomic Bomb Survivors. Part II: Solid Tumors, 1958-1987

1994 601 citations Desmond Thompson et al. profile →
Cancer Incidence in Atomic Bomb Survivors. Part III: Leukemia, Lymphoma and Multiple Myeloma, 1950-1987

1994 576 citations Desmond Thompson et al. profile →

Peers

Desmond Thompson

OSM

ONCOL

SURGE

RNMI

David L. Kendler Canada

Saeko Fujiwara Japan

Arthur C. Santora United States

David Karpf United States

Peter Selby United Kingdom

Stephen F. Hodgson United States

Peyman Hadji Germany

Thomas A. Abbott United States

Thomas L. Nickolas United States

Sophie A. Jamal Canada

David L. Kendler Canada

Desmond Thompson

9.0k ×1.2

OSM

6.4k ×1.2

ONCOL

4.2k ×1.6

2.6k ×1.0

SURGE

463 ×0.3

RNMI

Citations per year, relative to Desmond Thompson Desmond Thompson (= 1×) peers David L. Kendler

Countries citing papers authored by Desmond Thompson

Since Specialization

Citations

This map shows the geographic impact of Desmond Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Desmond Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Desmond Thompson more than expected).

Fields of papers citing papers by Desmond Thompson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Desmond Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Desmond Thompson. The network helps show where Desmond Thompson may publish in the future.

Co-authorship network of co-authors of Desmond Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of Desmond Thompson. A scholar is included among the top collaborators of Desmond Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Desmond Thompson. Desmond Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moshfeghi, Darius M., Desmond Thompson, & Namrata Saroj. (2019). Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies. British Journal of Ophthalmology. 104(9). 1223–1227. 3 indexed citations

Ginsberg, Henry N., Jaakko Tuomilehto, G. Kees Hovingh, et al.. (2019). Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovascular Drugs and Therapy. 33(1). 69–76. 9 indexed citations

Taskinen, Marja‐Riitta, Stefano Del Prato, Maja Bujas‐Bobanovic, et al.. (2018). Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Atherosclerosis. 276. 124–130. 24 indexed citations

Kereiakes, Dean J., Norman E. Lepor, Robert Gerber, et al.. (2018). Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials. Atherosclerosis. 277. 211–218. 11 indexed citations

Catapano, Alberico L., L. Veronica Lee, Michael J. Louie, et al.. (2017). Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. Scientific Reports. 7(1). 45788–45788. 13 indexed citations

Jaffe, Glenn J., Peter K. Kaiser, Desmond Thompson, et al.. (2016). Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid. Ophthalmology. 123(9). 1856–1864. 53 indexed citations

Freund, K. Bailey, Quan V. Hoang, Namrata Saroj, & Desmond Thompson. (2015). Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab. Ophthalmology. 122(9). 1802–1810. 47 indexed citations

Leary, Alison, et al.. (2008). An analysis of use of crowd medical services at an English football league club. International Emergency Nursing. 16(3). 193–199. 10 indexed citations

Bonnick, Sydney Lou, Kenneth G. Saag, Douglas P. Kiel, et al.. (2006). Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years. Obstetrical & Gynecological Survey. 62(1). 35–36. 5 indexed citations

10.

Rosen, Clifford J., Marc C. Hochberg, Sydney Lou Bonnick, et al.. (2005). Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study. Journal of Bone and Mineral Research. 20(1). 141–151. 21 indexed citations

11.

Papapoulos, Socrates E., Sara A. Quandt, Uri Liberman, Marc C. Hochberg, & Desmond Thompson. (2004). Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporosis International. 16(5). 468–474. 105 indexed citations

12.

Sebba, Anthony, Sydney Lou Bonnick, Risa Kagan, et al.. (2004). Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Current Medical Research and Opinion. 20(12). 2031–2041. 44 indexed citations

13.

Ravn, Pernille, Desmond Thompson, Philip D. Ross, & Claus Christiansen. (2003). Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone. 33(1). 150–158. 46 indexed citations

14.

Cauley, Jane A., Desmond Thompson, Kristine E. Ensrud, Jean C. Scott, & Dennis M. Black. (2000). Risk of Mortality Following Clinical Fractures. Osteoporosis International. 11(7). 556–561. 735 indexed citations breakdown →

15.

Ensrud, Kristine E., Desmond Thompson, Jane A. Cauley, et al.. (2000). Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass. Journal of the American Geriatrics Society. 48(3). 241–249. 370 indexed citations

16.

Vogt, Thomas, Philip D. Ross, Lisa Palermo, et al.. (2000). Vertebral Fracture Prevalence Among Women Screened for the Fracture Intervention Trial and a Simple Clinical Tool to Screen for Undiagnosed Vertebral Fractures. Mayo Clinic Proceedings. 75(9). 888–896. 75 indexed citations

17.

Wasnich, Richard D., Philip D. Ross, Desmond Thompson, Giovanni Cizza, & A.J.P. Yates. (1999). Skeletal Benefits of Two Years of Alendronate Treatment Are Similar for Early Postmenopausal Asian and Caucasian Women. Osteoporosis International. 9(5). 455–460. 20 indexed citations

18.

Ravn, Pernille, D. J. Hosking, Desmond Thompson, et al.. (1999). Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study¹. The Journal of Clinical Endocrinology & Metabolism. 84(7). 2363–2368. 113 indexed citations

19.

Nevitt, Michael C., et al.. (1999). Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. Bone. 25(5). 613–619. 125 indexed citations

20.

Black, Dennis M., Steven R. Cummings, David Karpf, et al.. (1996). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. The Lancet. 348(9041). 1535–1541. 2935 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact